Purpose <p>This study was conducted to assess the clinical significance of programmed cell death-ligand 1 (PD-L1)-positive circulating tumor cells (CTCs) as predictive biomarkers for the efficacy of PD-(L)1 inhibitor-based treatment in advanced hepatocellular carcinoma (HCC).</p> Experimental design <p>We enrolled 59 patients with unresectable HCC who received immunotherapy-based treatment and analyzed CTCs, PD-L1<sup>+</sup>CTCs and molecules in peripheral blood. An innovative telomerase…
PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy
Journal for ImmunoTherapy of Cancer | | Gong, C., You, S., Zhang, Q., Yang, Z., Bi, X., Zhao, H., Sun, Y., Zhou, J., Rong, W., Zhao, J., Zhang, K., Zhou, A., Zhang, W., Zhang, W.
Topics: skin-cancer, liver-cancer, cervical-cancer, immunotherapy, targeted-therapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer